This is the press release:
BioMarin Enrolls First Participant in Phase 3 Trial of Vosoritide for Treatment of Children with Achondroplasia
SAN RAFAEL, Calif., Dec. 12, 2016 (GLOBE NEWSWIRE) --
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the
company has initiated a global Phase 3 study for vosoritide, an analog
of C-type Natriuretic Peptide (CNP), in children with achondroplasia,
the most common form of dwarfism. The first child enrolled in the study
was at a site in Australia.
"Based on the positive results
seen in our Phase 2 study, we look forward to continuing to investigate
vosoritide," said Hank Fuchs, M.D., President, Worldwide Research and
Development at BioMarin. "We are grateful to the children and their
families, who have participated in the earlier study and are
participating in this Phase 3 study."The Phase 3 study is a randomized, placebo-controlled study of vosoritide in approximately 110 children with achondroplasia ages 5-14 for 52 weeks. The study will be followed by a subsequent open-label extension. Children in this study will have completed a minimum six-month baseline study to determine their respective baseline growth velocity prior to entering the Phase 3 study. Vosoritide is being tested in children whose growth plates are still open. This is approximately 25 percent of people with achondroplasia.
The primary endpoint of the study is the change in growth velocity from baseline over one year in children treated compared to placebo. The company also plans to augment the growth velocity data with assessments of proportionality and functionality.
In addition, BioMarin is planning a separate Phase 2 study evaluating the effect of vosoritide in infants and toddlers. Vosoritide has been granted orphan drug designation in both the United States and Europe.
(...)
Here goes a link for the complete press release:
http://investors.bmrn.com/releasedetail.cfm?ReleaseID=1003715
